GSE113082
Next Generation Sequencing analysis of control and serotonin, pergolide and dexfenfluramine treated tricuspid valves
Identify biological processes leading to heart valve disease upon long-term oral administration of serotonin, pergolide and dexfenfluramine Transcriptome profiling of tricuspid valves isolated from the drug treateds rabbit groups and compared to control rabbits using RNA sequencing Distinct patterns of differentially expressed genes (DEGs) highlight common and specific biological processes of drug treatment in tricuspid valves Overall design: Total RNA, extracted from tricuspid heart valves (n=5 for each treatment and control),  was sequenced with an Illumina NextSeq500 sequencer generating a total of around 10 millions mapped reads per library on average.